PT  - JOURNAL ARTICLE
AU  - Blacutt, Miguel
AU  - Filgueiras Gonçalves, Alberto José
AU  - Stults-Kolehmainen, Matthew
TI  - Prevalence and Incidence of Stress, Depression and Anxiety Symptoms among Brazilians in Quarantine across the early phases of the COVID-19 Crisis
AID  - 10.1101/2021.09.07.21263246
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.07.21263246
4099  - http://medrxiv.org/content/early/2021/09/12/2021.09.07.21263246.short
4100  - http://medrxiv.org/content/early/2021/09/12/2021.09.07.21263246.full
AB  - Objective The aim of this study was to measure the prevalence and incidence of stress, depression, and anxiety symptoms in Brazilians during the COVID-19 pandemic.Method We assessed 103 (54 women, 49 men) participants online in three periods of the epidemic curve: time 1 (T1; first cases of community transmission; March 20 to 25, 2020), time 2 (T2; acceleration; April 15 to 20, 2020) and time 3 (T3; continued acceleration; June 25 to 30, 2020). The criteria adopted for calculating prevalence and incidence was identifying participants with scores two standard deviations above the mean compared to normative data. Stress was measured using the Perceived Stress Scale (PSS-10), depression was measured using the Filgueiras Depression Index (FDI), and anxiety was measured using the State-Trait Anxiety Inventory – State Subscale (STAI-S).Results Initially, 89% of individuals were free of severe stress, anxiety, and depression, which dropped to 35% by T3. Prevalence of stress increased from 1.9% (95% CI [0.5, 6.8]) at T1 to 7.8% (95% CI [4.0, 14.6]) at T2, and 28.2% (95% CI [20.4, 37.5]) at T3. Depression prevalence increased from 0% (95% CI [0, 3.6]) at T1 to 23.3% (95% CI [16.2, 32.3]) at T2 and 25.2% (95% CI [17.8, 34.4]) at T3. The prevalence of severe anxiety-state symptoms increased from 10.7% (95% CI [6.1, 18.1]) at T1 to 11.7% (95% CI [6.8, 19.3]) at T2 and 45.6% (95% CI [36.3, 55.2]) at T3. Stress incidence increased by 7.8% (95% CI = [4, 14.6]) from time 1 to time 2, 23.3% (95% CI [16.2, 32.3]) from time 2 to time 3, and 26.2% (95% CI [18.7, 35.5]) from time 1 to time 3. Depression incidence increased by 23.3% (95% CI [16.2, 32.3]) from T1 to T2, 15.5 (95% CI [9.8, 23.8]) T2 to T3, and 25.2% (95% CI [17.8, 34.4]) from T1 to T3. Anxiety incidence increased by 9.7% (95% CI [5.4, 17]) from T1 to T2, 39.8% (95%CI [30.9, 49.5]) from T2 to T3, and 35.9% (95% CI [27.3, 45.5]) from T1 to T3. The severity of stress significantly increased from 16.1±8.7 at T1 to 23.5±8.4 at T2, and 30.3±6.0 at T3. Depression severity significantly increased from 48.5±20.5 at T1 to 64.7±30.2 at T2, and 75.9±26.1 at T3. Anxiety increased from 49.0±13.4 at T1 to 53.5±12.5 at T2 and 62.3±13.4 at T3. Females and individuals without comorbidities that increased COVID-19 lethality had higher anxiety scores than males and individuals with comorbidities. Age was inversely associated with mental health outcomes at baseline.Conclusion The prevalence and severity of stress, depression, and anxiety significantly increased throughout the course of the pandemic. Anxiety seems to be sensitive to gender and risk status, where females and individuals without pre-existing comorbidities had higher anxiety by the final collection point. Depression and stress increased throughout time but were not different between genders or risk status.HighlightsPerceived stress, depression and anxiety symptoms were assessed in 103 participants at three points in the COVID-19 pandemicParticipants showed higher prevalence of depression, stress, and anxiety throughout progression of the pandemicOnly 35% of individuals were free of severe stress, anxiety, and depression the third data collection point – even though 89% were free of these conditions at the startFemale and individuals without a comorbidity that increased risk of COVID-19 fatality had greater anxiety by the third time point compared to males, and those with a comorbidityCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was used for this manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee at Rio de Janeiro State University approved all procedures (report #2.990.087).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon reasonable request